Ahmed Elgebaly

Dr. Ahmed Elgebaly

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2016 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
AEAhmed Elgebaly
Ahmed Elgebaly
AEAhmed Elmaraezy
Ahmed Elmaraezy
AKAdham M. Khalil
Adham M. Khalil
AAAhmed M. A. Altibi
Ahmed M. A. Altibi
KHKenji Hirayama
Kenji Hirayama
Several different interventions have been examined to alleviate pain and reduce frequency of trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible emerging choice of treatment for TN. We conducted an electronic search in 10 databases/electronic search engines to access relevant publications. All articles in all languages reporting RCTs on the efficacy and safety of BTX-A in the treatment of TN were included for systematic review and meta-analysis. A total of four RCTs (n = 178) were identified for final meta-analysis. The overall effect favored BTX-A versus placebo in terms of proportion of responders (risk ratio RR = 2.87, 95 % confidence interval CI [1.76, 4.69], p <0.0001) with no significant detected heterogeneity (p = 0.31; I2 = 4 %). Paroxysms frequency per day was significantly lower for BTX-A group (mean difference MD = -29.79, 95 % CI [-38.50,–21.08], p <0.00001) with no significant heterogeneity (p = 0.21; I2 = 36 %). Despite limited data, our results suggest that BTX-A may be an effective and safe treatment option for patients with TN. Further larger and well-designed RCTs are encouraged to translate these findings into better clinical outcome and better quality of life for TN patients.

13 May 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
AEAhmed Elmaraezy
Ahmed Elmaraezy
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
AMAbdelrhman Tarek Mohammed
Abdelrhman Tarek Mohammed
AAAhmed Al‐Habbaa
Ahmed Al‐Habbaa
AEAhmed Elgebaly
Ahmed Elgebaly
KHKenji Hirayama
Kenji Hirayama

1 March 2017 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
AEAhmed Elgebaly
Ahmed Elgebaly
IRIbrahim A. I. Radwan
Ibrahim A. I. Radwan
MAMohamed M. AboElnas
Mohamed M. AboElnas
HIHamza H. Ibrahim
Hamza H. Ibrahim
MEMoutaz F. M. Eltoomy
Moutaz F. M. Eltoomy
AOAmr A. Othman
Amr A. Othman
Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

25 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HVHuy Gia Vuong
Huy Gia Vuong
AAAhmed M.A. Altibi
Ahmed M.A. Altibi
AAAmr Hesham Abdelhamid
Amr Hesham Abdelhamid
PNPhuong Uyen Duong Ngoc
Phuong Uyen Duong Ngoc
VQVo Duy Quan
Vo Duy Quan
TKTetsuo Kondo
Tetsuo Kondo
Background: The genetic alterations of papillary thyroid carcinoma (PTC) have been reported to change over the past few decades. We performed this systematic review to further examine the trends and modifications of patient demographic, clinicopathological features and molecular profiles of PTC over time.

5 April 2018 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
Mohannad EledreesiMohannad Eledreesi
Mohannad Eledreesi
TDThomas M. Drake
Thomas M. Drake
JCJulian Camilleri-Brennan
Julian Camilleri-Brennan
STStephen Tabiri
Stephen Tabiri
SFStuart J. Fergusson
Stuart J. Fergusson
EEEugenio Grasset Escobar
Eugenio Grasset Escobar
Background: Appendicitis is the most common abdominal surgical emergency worldwide. Differences between high- and low-income settings in the availability of laparoscopic appendectomy, alternative management choices, and outcomes are poorly described. The aim was to identify variation in surgical management and outcomes of appendicitis within low-, middle-, and high-Human Development Index (HDI) countries worldwide. Methods: This is a multicenter, international prospective cohort study. Consecutive sampling of patients undergoing emergency appendectomy over 6 months was conducted. Follow-up lasted 30 days. Results: 4546 patients from 52 countries underwent appendectomy (2499 high-, 1540 middle-, and 507 low-HDI groups). Surgical site infection (SSI) rates were higher in low-HDI (OR 2.57, 95% CI 1.33–4.99, p = 0.005) but not middle-HDI countries (OR 1.38, 95% CI 0.76–2.52, p = 0.291), compared with high-HDI countries after adjustment. A laparoscopic approach was common in high-HDI countries (1693/2499, 67.7%), but infrequent in low-HDI (41/507, 8.1%) and middle-HDI (132/1540, 8.6%) groups. After accounting for case-mix, laparoscopy was still associated with fewer overall complications (OR 0.55, 95% CI 0.42–0.71, p < 0.001) and SSIs (OR 0.22, 95% CI 0.14–0.33, p < 0.001). In propensity-score matched groups within low-/middle-HDI countries, laparoscopy was still associated with fewer overall complications (OR 0.23 95% CI 0.11–0.44) and SSI (OR 0.21 95% CI 0.09–0.45). Conclusion: A laparoscopic approach is associated with better outcomes and availability appears to differ by country HDI. Despite the profound clinical, operational, and financial barriers to its widespread introduction, laparoscopy could significantly improve outcomes for patients in low-resource environments. Trial registration: NCT02179112.

1 February 2018 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
AMAmr Menshawy
Amr Menshawy
OMOmar Mattar
Omar Mattar
AAAli Abdulkarim
Ali Abdulkarim
SKShiref Kasem
Shiref Kasem
NNNoha Nasreldin
Noha Nasreldin
AEAhmed Elgebaly
Ahmed Elgebaly